Malin Life Sciences Holdings Ltd 4
4 · Poseida Therapeutics, Inc. · Filed Jul 15, 2020
Insider Transaction Report
Form 4
Malin Life Sciences Holdings Ltd
10% Owner
Transactions
- Conversion
Common Stock
2020-07-14+1,168,985→ 8,182,903 total - Conversion
Series A Preferred Stock
2020-07-14−8,746,356→ 0 total→ Common Stock (7,013,918 underlying) - Conversion
Series A-1 Preferred Stock
2020-07-14−1,457,725→ 0 total→ Common Stock (1,168,985 underlying) - Conversion
Series C Preferred Stock
2020-07-14−392,927→ 0 total→ Common Stock (315,098 underlying) - Conversion
Common Stock
2020-07-14+315,098→ 9,188,125 total - Conversion
Series B Preferred Stock
2020-07-14−860,585→ 0 total→ Common Stock (690,124 underlying) - Conversion
Common Stock
2020-07-14+7,013,918→ 7,013,918 total - Conversion
Common Stock
2020-07-14+690,124→ 8,873,027 total
Footnotes (2)
- [F1]All shares of preferred stock, $0.0001 par value per share, of the Issuer, (i) had no expiration date and (ii) automatically converted into the Issuer's common stock, $0.0001 par value per share, on a 1-for-0.8019246 basis immediately prior to the closing of the Issuer's initial public offering.
- [F2]Malin Life Sciences Holdings Ltd, the record holder of the shares, is a wholly owned subsidiary of Malin Corporation plc. Malin Corporation plc may be deemed to beneficially own the shares and may be deemed to share voting and dispositive power over these shares.